Navigation Links
IRIDEX Reports Third Quarter Financial Results
Date:11/19/2007

MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the quarter ended September 29, 2007. Revenue for the period was $13.6 million, a 47% increase from the $9.2 million reported for the third quarter of 2006. The Company's net loss was $1.2 million or $0.15 per diluted share for the third quarter of 2007 compared with a loss of $1.1 million or a loss of $0.15 per diluted share in the third quarter of 2006. The prior year financial results do not include the AMS/Laserscope aesthetic acquisition completed on January 16, 2007.

Theodore A. Boutacoff, President and CEO stated, "While neither I nor the other members of the board of directors are satisfied with the Company's recent performance, IRIDEX has taken numerous actions that we believe have put the Company back on track. These actions include:

-- Strengthening the Company's cash position via a private placement with

net proceeds to the Company of $4.9 million. At the end of the third

quarter, IRIDEX' total cash position was $9.6 million (including

$3.8 million restricted to support our bank term loan).

-- Reducing operating expenses as a percentage of revenue to 53.3% during

the third quarter of 2007 from 59.9% in the second quarter.

-- Improving gross margins to 45.6% in the third quarter 2007 from 43.2%

in the second quarter 2007.

-- Reaching agreement with AMS on the major elements of the Laserscope

acquisition. This agreement included approximately a $2.7 million

reduction in the acquisition purchase price to be paid and decreased

the final inventory to be purchased from AMS to $4.1 million from the

originally agreed upon amount of up to $9.0 million.

-- Successfully continuing the transfer of the Laserscope products we

intend to manufacture into our Mountain View facility. Completion of

this integration during our fourth quarter is expected to add to gross

margin in subsequent quarters.

-- Adding two experienced outside members, James B. Hawkins and William M.

Moore, to our board of directors. Both have substantial operating

experience with growing medical device companies and have already made

contributions as board members.

-- Expecting the receipt of an additional $4 million in cash from the

settlement of the litigation with Synergetics. This litigation had

contributed significantly to the Company's expenses and losses during

the prior periods. Under the settlement, Synergetics paid IRIDEX $2.5

million on April 16, 2007 and agreed to additional annual payments of

$800,000 on each April 16th until 2012."

Mr. Boutacoff continued, "This has been a difficult year for IRIDEX, our employees and our shareholders. We have and will continue to take decisive actions to improve operations, to provide value to our customers and to create value for our shareholders. A key area of focus will be addressing remaining issues and challenges relating to our expanded aesthetics business following the Laserscope acquisition."

Revenue for the nine-month period ended September 29, 2007 was $41.4 million compared with the $26.9 million reported for the same period of 2006. Net loss for the nine-month period ended September 29, 2007 was $6.5 million or $0.80 per diluted share compared with a net loss of $2.0 million or a loss of $0.26 per diluted share during the comparable period of 2006.

Ophthalmology sales were $7.9 million for the third quarter of 2007 compared to $8.0 million reported in the third quarter of 2006. Aesthetics sales grew to $5.7 million for the third quarter of 2007, up from $1.3 million for the corresponding quarter in 2006.

During the third quarter of 2007 domestic sales increased 26% to $7.2 million compared to $5.7 million for the third quarter of 2006; and international sales grew 80% to $6.4 million compared to $3.5 million for the third quarter of 2006. International sales are denominated in US dollars except for sales from the Company's subsidiaries in the UK and France, foreign currency fluctuations had no material impact.

Conference Call

IRIDEX management will conduct a conference call later today, Monday, November 19th at 5:00 p.m. EST. Interested parties may access the live conference call via telephone by dialing (800) 218-0713 (US) or (303) 262-2140 (International), or by visiting the Company's website at http://www.iridex.com. A telephone replay will be available beginning on Monday, November 19 through Monday, November 26, 2007 by dialing (800) 405-2236 (US) or (303) 590-3000 (International) and entering Passcode 11102345#. In addition, an archived version of the webcast will be available beginning November 19, 2007 on the Company's website at http://www.iridex.com.

About IRIDEX

IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, disposable laser probes and delivery devices to treat eye diseases in ophthalmology and skin disorders in the aesthetics market. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 97 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, relating to the Company's growth strategy and prospects, revenues, gross margins, and earnings, expenses, integrating the aesthetics business acquired from Laserscope and realizing efficiencies and synergies relating thereto, controlling costs, managing cash, and addressing our liquidity and capital resource needs. Actual results could differ materially and adversely from those projected in the forward-looking statements contained in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the fiscal year ended December 30, 2006 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

IRIDEX Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(unaudited)

Three Months Ended Nine Months Ended

September September September September

29, 30, 29, 30,

2007* 2006 2007* 2006

Sales $13,575 $9,222 $41,390 $26,869

Cost of sales 7,390 4,350 23,412 13,076

Gross profit 6,185 4,872 17,978 13,793

Operating expenses:

Research and development 1,319 1,506 4,636 3,955

Sales, general and administrative 5,920 4,854 21,740 12,651

Total operating expenses 7,239 6,360 26,376 16,606

Income (loss) from operations (1,054) (1,488) (8,398) (2,813)

Legal settlement 0 0 2,500 0

Interest and other income, net (184) 184 (603) 540

Income (loss) before income taxes (1,238) (1,304) (6,501) (2,273)

Benefit from (provision for)

income taxes 0 161 0 293

Net income (loss) ($1,238) ($1,143) ($6,501) ($1,980)

Net income (loss) per common

share - basic & diluted ($0.15) ($0.15) ($0.80) ($0.26)

Shares used in per common share

basic & diluted calculations 8,218 7,758 8,165 7,680

* Includes the impact of FAS123(R).

IRIDEX Corporation

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

September 29, December 30,

2007 2006

Assets (unaudited)

Current Assets:

Cash and cash equivalents $5,795 $21,051

Restricted cash 3,800 -

Accounts receivable, net 8,516 6,052

Inventories 13,250 9,499

Prepaids and other current assets 2,053 1,264

Total current assets 33,414 37,866

Property and equipment, net 1,840 1,087

Goodwill 10,509 -

Other intangibles, net 14,488 -

Other long term debt 299 1,224

Total assets $60,550 $40,177

Liabilities and Stockholders' Equity

Current Liabilities:

Accounts payable $3,552 $1,830

Short term debt 5,110 -

Accounts compensation 1,540 1,517

Accrued expenses 4,435 2,392

Accrued warranty 2,182 866

Deferred revenue 3,977 1,415

Current portion of long term debt 5,311 -

Total current liabilities 26,107 8,020

Stockholders' Equity:

Preferred stock 5 -

Common stock 83 79

Additional paid-in capital 38,500 29,697

Accumulated other comprehensive loss (25) -

Treasury stock (430) (430)

Retained earnings (3,690) 2,811

Total stockholders' equity 34,443 32,157

Total liabilities and stockholders'

equity $60,550 $40,177

Contact: Theodore A. Boutacoff

President and CEO

650-940-4700


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. IRIDEX Announces Closing of $5.0 Million Private Placement
2. William Moore Appointed to IRIDEX Board of Directors
3. IRIDEX Appoints Burr, Pilger & Mayer New Independent Auditor
4. James B. Hawkins Appointed to IRIDEX Board of Directors
5. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
6. IRIDEX Announces Third Quarter 2007 Conference Call and Release Date
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
(Date:6/23/2016)... WASHINGTON , June 23, 2016  The ... Pharmaceuticals has joined the health policy research organization ... Steven Romano , MD, senior vice president and ... his company,s representative on the NPC Board of ... are pleased that Mallinckrodt has joined us in ...
Breaking Medicine Technology: